Bei Akademie registrieren
AbbVie Inc., US00287Y1091

AbbVie stock: Oxford expansion broadens UK drug research

Published on 11/04/2026 at 16:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie stock returns to focus as the drugmaker expands its Oxford research footprint. The project supports wider UK life-sciences investment.

Oxford Expansion Adds Research Capacity

  • AbbVie is expanding research capabilities in immunology, neuroscience and oncology at a new Oxford site.
  • The facility builds on capabilities gained through the 2022 acquisition of DJS Antibodies.
  • AbbVie works with more than 100 UK universities and research organisations each year.
AbbVie Inc., US00287Y1091, Illustration mit AI erstellt.
AbbVie Inc., US00287Y1091, Illustration mit AI erstellt.

AbbVie is expanding its Oxford research footprint as the US drugmaker broadens its capabilities in immunology, neuroscience and oncology. AbbVie announced the expansion on Wednesday, November 4, 2026, according to Reuters.

New Oxford Site Broadens Research

The new AbbVie Oxford facility covers 12,000 square feet and forms part of a UK investment of more than GBP 120 million. The site is intended to strengthen research into new disease targets and combination therapies in areas with significant unmet medical needs.

The expansion builds on capabilities gained through AbbVie's 2022 acquisition of Oxford-based DJS Antibodies. The move deepens the drugmaker's presence in the city's life-sciences ecosystem and adds capacity to its wider research and development network.

UK Partnerships Support Drug Development

AbbVie works with more than 100 universities and research organisations across the UK each year. Its collaboration with the University of Oxford examines how patients with certain inflammatory diseases respond to treatment over the course of their illness, with the findings intended to guide future drug development.

The company employs more than 1,100 people across its UK operations in Oxford, Maidenhead and Marlow. For investors, the announcement highlights longer-term research capacity and external collaboration rather than a separately quantified near-term revenue contribution.

The real-time quote of AbbVie stock traded at 253.85 euros on Lang & Schwarz at 16:04 CET on Wednesday, November 4, 2026.

AbbVie Inc. Stock Facts

  • Company: AbbVie Inc.
  • ISIN: US00287Y1091
  • Trading venue: Lang & Schwarz
  • Quote: 253.85 euros at 16:04 CET on Wednesday, November 4, 2026

Broader US market sentiment can be followed in current S&P 500 market reports.

More news and analyses are available on AbbVie stock.

Disclaimer...
en | US00287Y1091 | ABBVIE INC. | boerse | 70457723 |